Use and side-effect profile of spironolactone in a private cardiologist's practice.

Clinical Cardiology
Eric M WilliamsMarcey R Karambelas

Abstract

The beneficial effects of spironolactone on the treatment of cardiovascular diseases are well known, but translating these benefits into private practice can be difficult because of the drug's side-effect profile. When patients are monitored over the long term, spironolactone can be used safely with an acceptable side-effect profile. We retrospectively studied 762 patients taking spironolactone over a 7-year period in a cardiologist's referral-based practice and monitored them for side effects from the medication. Data were available on 762 patients. The average age of our patients when started on the medication was 67.2 +/- 0.5 years. Of these, 585 (76.8%) patients were treated for heart failure and 155 (20.3%) for hypertension. An average dose of 38.4 +/- 1.4 mg of spironolactone was used for treatment of all conditions. Of the 762 patients, 81 (10.6%) experienced side effects while using the medication; 40 had hyperkalemia (5.3%), 14 had gynecomastia (1.8%), and 15 had gastritis (2%). Of the patients with hyperkalemia, average creatinine clearance decreased from 64.6 +/- 5.8 ml/min at therapy start to 50.3 +/- 5.5 ml/min at the time of onset of side effects. Spironolactone can be used with an acceptable side-effect profile a...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Dec 1, 1981·The Journal of Endocrinology·J StaessenA Amery
Jan 5, 2002·The New England Journal of Medicine·K T Weber
Jul 11, 2002·Journal of the American College of Cardiology·Mariantonietta CicoiraPiero Zardini
Jan 22, 2003·Journal of the American College of Cardiology·Biykem BozkurtA A Knowlton
Jan 22, 2003·Journal of the American College of Cardiology·W H Wilson Tang, Gary S Francis
Feb 25, 2003·Journal of the American College of Cardiology·Shu KasamaMasahiko Kurabayashi
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
May 21, 2003·Circulation·Nancy J Brown
Aug 6, 2004·The New England Journal of Medicine·David N JuurlinkDonald A Redelmeier

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Hypertension Reports·Richard E KatholiPaul A Sobotka
Dec 28, 2016·Journal of Pain and Symptom Management·Laura CaroneAndrew Wilcock
Mar 11, 2008·Pharmacoepidemiology and Drug Safety·Antonio RussoLuigi Bisanti
Mar 7, 2019·European Heart Journal Supplements : Journal of the European Society of Cardiology·Faiez ZannadBertram Pitt
Aug 1, 2020·Journal of Human Hypertension·Morag J YoungJun Yang
Jun 8, 2021·Frontiers in Oncology·José A Carlos-EscalanteTalia Wegman-Ostrosky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Asterios KaragiannisVassilios Gabriel Athyros
Molecular and Cellular Endocrinology
Susan M Garthwaite, Ellen G McMahon
© 2022 Meta ULC. All rights reserved